Prognostic Significance of +1q Alterations in Relapsed/Refractory Multiple Myeloma Treated With Daratumumab‐, Elotuzumab‐, and Carfilzomib‐Based Triplet Regimens: A Multicenter Real‐World Analysis of 635 Patients
European Journal of Haematology · 2025
DOI: 10.1111/ejh.14413 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift European Journal of Haematology, 2025. Verfasst von Fortunato Morabito und 59 weiteren Autor:innen. Beteiligte Einrichtung: Gruppo Amici Dell'Ematologia Foundation-GrADE, Reggio Emilia, Italy. Hauptthemen laut MEDLINE: Multiple Myeloma, Antineoplastic Combined Chemotherapy Protocols, Chromosomes, Human, Pair 1, Chromosome Aberrations. Die Arbeit nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Relapsed/refractory multiple myeloma (RRMM) research on the impact of +1q abnormalities in real‐world settings is limited. This study evaluated the prognostic and predictive significance of 1q gain [gain(1q)] and amplification [ampl(1q)] in 635 RRMM patients treated with daratumumab‐, elotuzumab‐, and carfilzomib‐based triplet regimens. Patients with +1q abnormalities had lower deep response rates [≥ CR: 9.4% for gain(1q), 11.6% for ampl(1q)] versus 20.2% in +1q‐negative patients. Multivariable ordinal logistic analysis showed significantly lower odds of achieving ≥ CR in patients with gain(1q) (OR = 0.49, p < 0.001) or ampl(1q) (OR = 0.58, p = 0.0037). Progression‐free survival (PFS) was longer in +1q‐negative patients (28 months) compared to those with gain(1q) (8 months) or ampl(1q) (7.4 months). Multivariable models identified gain(1q) (HR = 1.9, p < 0.001) and ampl(1q) (HR = 2.2, p < 0.001) as independent negative prognostic factors alongside del17p, t (4;14), creatinine clearance < 60 mL/min, and ISS Stages II and III. Similarly, overall survival (OS) was reduced for patients with gain(1q) (25 months) and ampl(1q) (19.5 months) versus 42.2 months in +1q‐negative patients. Multivariable analysis showed gain(1q) (HR = 1.6, p = 0.007) and ampl(1q) (HR = 2.0, p = 0.002) as independent predictors of increased mortality. Ancillary +1q abnormalities associated with high‐risk cytogenetic changes were linked to both shorter PFS and OS. Stratification into no‐hit, single‐hit, double‐hit, and triple‐hit groups showed significant survival differences, emphasizing the impact of cumulative cytogenetic abnormalities on outcomes. In conclusion, +1q abnormalities significantly impact prognosis in RRMM and should be considered in risk stratification. The study emphasizes the importance of comprehensive cytogenetic profiling in real‐world settings and highlights the need for personalized treatment strategies to improve patient outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Gruppo Amici Dell'Ematologia Foundation-GrADE, Reggio Emilia, Italy.
- Hematology Unit AO of Cosenza, Cosenza, Italy.
- Hematology and Bone Marrow Transplant Unit, ASST Papa Giovanni XXIII, Bergamo, Italy.
- Hematology Unit, Ancona, Italy.
- Department of Medicine (DIMED), Hematology and Clinical Immunology, Padua University School of Medicine, Padova, Italy.
- Division of Hematology, AOU Città Della Salute e Della Scienza di Torino, University of Torino, Torino, Italy.
ORCID-Profile: Fortunato Morabito, Massimo Offidani, Nicola Sgherza, Gregorio Barilà, Angelo Belotti, Alessandro Gozzetti, Niccolò Bolli, Antonella Bruzzese, Katia Mancuso, Emiliano Barbieri
Zitieren
APA
Morabito, F., Martino, E. A., Galli, M., Offidani, M., Zambello, R., Bringhen, S., Giuliani, N., Califano, C., Brunori, M., Gagliardi, A., Sgherza, N., Quinto, A. M., Barilà, G., Belotti, A., Cerchione, C., Casaluci, G. M., Fontana, R., Bongarzoni, V., Tarantini, G., …, & Palumbo, M. (2025). Prognostic Significance of +1q Alterations in Relapsed/Refractory Multiple Myeloma Treated With Daratumumab‐, Elotuzumab‐, and Carfilzomib‐Based Triplet Regimens: A Multicenter Real‐World Analysis of 635 Patients. European Journal of Haematology. https://doi.org/10.1111/ejh.14413
Vancouver
Morabito F, Martino EA, Galli M, Offidani M, Zambello R, Bringhen S, et al. Prognostic Significance of +1q Alterations in Relapsed/Refractory Multiple Myeloma Treated With Daratumumab‐, Elotuzumab‐, and Carfilzomib‐Based Triplet Regimens: A Multicenter Real‐World Analysis of 635 Patients. European Journal of Haematology. 2025. doi:10.1111/ejh.14413
BibTeX
@article{Morabito2025,
author = {Morabito, Fortunato and Martino, Enrica Antonia and Galli, Monica and Offidani, Massimo and Zambello, Renato and Bringhen, Sara and Giuliani, Nicola and Califano, Catello and Brunori, Marino and Gagliardi, Alfredo and Sgherza, Nicola and Quinto, Angela Maria and Barilà, Gregorio and Belotti, Angelo and Cerchione, Claudio and Casaluci, Gloria Margiotta and Fontana, Raffaele and Bongarzoni, Velia and Tarantini, Giuseppe and Derudas, Daniele and Patriarca, Francesca and Gozzetti, Alessandro and Sementa, Adelina and Antonioli, Elisabetta and Rago, Angela and Lotti, Flavia and De Magistris, Claudio and Petrucci, Maria Teresa and Pettine, Loredana and Bolli, Niccolò and Conticello, Concetta and Zamagni, Elena and Palmieri, Salvatore and Musso, Maurizio and Mele, Anna and Della Pepa, Roberta and Vigna, Ernesto and Bruzzese, Antonella and Fazio, Francesca and Mina, Roberto and Paris, Laura and Vincelli, Iolanda Donatella and Farina, Giuliana and Cangialosi, Clotilde and Mancuso, Katia and Falcone, Antonietta Pia and Mele, Giuseppe and Sica, Antonello and Morè, Sonia and Reddiconto, Giovanni and Tripepi, Giovanni and D'Arrigo, Graziella and Barbieri, Emiliano and Quaresima, Micol and Cartia, Claudio Salvatore and Pezzatti, Sara and Marcatti, Magda and Farina, Francesca and Cafro, Anna and Palumbo, Michele},
title = {Prognostic Significance of +1q Alterations in Relapsed/Refractory Multiple Myeloma Treated With Daratumumab‐, Elotuzumab‐, and Carfilzomib‐Based Triplet Regimens: A Multicenter Real‐World Analysis of 635 Patients},
journal = {European Journal of Haematology},
year = {2025},
doi = {10.1111/ejh.14413}
}
EUVIMED